Adage Capital Partners
AXSM icon

Adage Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

Adage Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63.4M Sell
259,034
-478,544
-65% -$104M 0.09% 224
2026
Q1 		$125M Buy
737,578
+370,000
+101% +$63.9M 0.19% 99
2025
Q4 		$67.1M Sell
367,578
-77,422
-17% -$10.8M 0.1% 193
2025
Q3 		$54M Sell
445,000
-2,000
-0.4% -$225K 0.09% 223
2025
Q2 		$46.7M Buy
447,000
+399,000
+831% +$42.2M 0.08% 251
2025
Q1 		$5.6M Sell
48,000
-12,000
-20% -$1.37M 0.01% 682
2024
Q4 		$5.08M Sell
60,000
-465,000
-89% -$42.8M 0.01% 716
2024
Q3 		$47.2M Sell
525,000
-205,000
-28% -$17.9M 0.08% 243
2024
Q2 		$58.8M Buy
730,000
+215,000
+42% +$15.9M 0.11% 193
2024
Q1 		$41.1M Buy
515,000
+150,000
+41% +$12.6M 0.08% 273
2023
Q4 		$29.1M Buy
365,000
+40,000
+12% +$2.67M 0.06% 329
2023
Q3 		$22.7M Sell
325,000
-119,417
-27% -$8.93M 0.05% 360
2023
Q2 		$31.9M Sell
444,417
-605,583
-58% -$44.7M 0.07% 283
2023
Q1 		$64.8M Sell
1,050,000
-15,000
-1% -$985K 0.15% 169
2022
Q4 		$82.1M Buy
1,065,000
+915,000
+610% +$54.7M 0.2% 128
2022
Q3 		$6.69M Sell
150,000
-633,662
-81% -$31.7M 0.02% 738
2022
Q2 		$30M Buy
783,662
+133,662
+21% +$4.23M 0.07% 300
2022
Q1 		$26.9M Buy
+650,000
New +$20.1M 0.05% 373
2020
Q4 		– Sell
-200,000
Closed -$14.3M – 809
2020
Q3 		$14.3M Hold
200,000
– – 0.04% 457
2020
Q2 		$16.5M Buy
200,000
+115,000
+135% +$8.85M 0.04% 430
2020
Q1 		$5M Buy
+85,000
New +$6.93M 0.01% 571

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Adage Capital Partners's AXSM Position: Q2 2026 in Review

Adage Capital Partners reduced its Axsome Therapeutics (AXSM) stake by 65% in Q2 2026, selling an estimated $104M and leaving 259,034 shares worth $63.4M. The position accounts for 0.09% of the portfolio, ranked #224.

Adage Capital Partners first reported a position in AXSM in Q1 2020 and has held it in 21 quarters since. The position peaked at $125M in Q1 2026. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Adage Capital Partners held 259,034 shares of Axsome Therapeutics worth $63.4M as of Q2 2026.
  • Adage Capital Partners sold 478,544 Axsome Therapeutics shares in Q2 2026, an estimated $104M.
  • Axsome Therapeutics made up 0.09% of Adage Capital Partners's portfolio in Q2 2026, its #224 holding.
  • Adage Capital Partners first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 21 quarters since.
  • Adage Capital Partners's Axsome Therapeutics position peaked at $125M in Q1 2026.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.